Tvardi Therapeutics, Inc. (TVRD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.91+3.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TVRD
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | — | — | 7.1 | 21.0 | 41.9 | 23.0 | 135.1 | 19.9 | 13.5 | 0.9 | 0.1 | 3.8 | 3.2 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 0.9 | 0.1 | 3.8 | 3.2 |
| Cost of Revenues | — | — | — | — | — | 0.0 | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 18.0 | 18.0 | 32.8 | 108.5 | 91.9 | 82.7 | 107.9 | 113.8 | 75.5 | 48.5 | 49.3 | 21.2 | 15.1 |
| Operating Income | (27.2) | (26.7) | (58.4) | (121.5) | (87.5) | (89.1) | 5.4 | (111.7) | (77.4) | (59.5) | (58.4) | (25.2) | (18.1) |
| Earnings from Continuing Operations | |||||||||||||
| Interest & Investment Income | — | 0.7 | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | — | (71.3) | (118.5) | (85.5) | (88.4) | 7.7 | (107.2) | (74.4) | (58.3) | (57.7) | (25.1) | (17.9) |
| Income Tax Expense | — | — | (0.4) | 0.0 | 0.0 | 0.0 | (0.7) | (0.8) | (0.4) | (0.2) | (0.5) | (0.4) | (0.2) |
| Net Income | |||||||||||||
| Net Income | (26.1) | (18.2) | (70.9) | (11.9) | (85.5) | (88.4) | 8.4 | (106.4) | (74.0) | (58.1) | (57.3) | (24.7) | (17.7) |
| Per Share | |||||||||||||
| Basic EPS | (2.78) | (2.46) | (15.53) | (26.26) | (19.12) | (1.74) | 0.18 | — | — | — | — | — | — |
| Diluted EPS | (2.78) | (3.26) | (15.53) | (26.26) | (19.12) | (1.74) | 0.18 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 9.4 | 7.4 | 4.6 | 4.5 | 4.5 | 50.7 | 47.4 | 42.7 | 35.9 | 31.2 | 27.3 | 24.6 | 21.0 |
| Diluted Weighted Avg Shares | 9.4 | 7.8 | 4.6 | 4.5 | 4.5 | 50.7 | 47.9 | 42.7 | 35.9 | 31.2 | 27.3 | 24.6 | 21.0 |
| Supplemental | |||||||||||||
| EBITDA | — | (26.7) | (58.2) | (121.2) | (87.3) | (88.8) | 5.6 | (111.5) | (77.0) | (59.0) | (56.9) | (24.3) | (17.3) |
| EBIT | (27.2) | (26.7) | (58.4) | (121.5) | (87.5) | (89.1) | 5.4 | (111.7) | (77.4) | (59.5) | (58.4) | (25.2) | (18.1) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | -9.0% | 0.8% | 0.5% | 0.3% | 0.8% | 1.6% | 1.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.